Review
doi: 10.1111/j.1464-410X.2005.05527.x.
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways
Affiliations
- PMID: 15892826
- DOI: 10.1111/j.1464-410X.2005.05527.x
Item in Clipboard
Review
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways
BJU Int.
2005 Jun.
Free article
No abstract available
Similar articles
-
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.BJU Int. 2005 Jun;95(9):1320-6. doi: 10.1111/j.1464-410X.2005.05526.x. BJU Int. 2005. PMID: 15892825 Review. No abstract available.
-
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.Cancer Res. 2000 Apr 15;60(8):2132-5. Cancer Res. 2000. PMID: 10786674
-
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.J Biol Chem. 2002 Mar 1;277(9):7076-85. doi: 10.1074/jbc.M108255200. Epub 2001 Dec 19. J Biol Chem. 2002. PMID: 11751884
-
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.Cancer Res. 2004 Oct 1;64(19):7156-68. doi: 10.1158/0008-5472.CAN-04-1121. Cancer Res. 2004. PMID: 15466214
-
Androgen receptor coactivators and prostate cancer.Adv Exp Med Biol. 2008;617:245-55. doi: 10.1007/978-0-387-69080-3_23. Adv Exp Med Biol. 2008. PMID: 18497048 Review. No abstract available.
Cited by
-
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.Cancer Manag Res. 2019 Aug 1;11:7253-7262. doi: 10.2147/CMAR.S165706. eCollection 2019. Cancer Manag Res. 2019. PMID: 31534371 Free PMC article.
-
Celastrol blocks interleukin-6 gene expression via downregulation of NF-κB in prostate carcinoma cells.PLoS One. 2014 Mar 24;9(3):e93151. doi: 10.1371/journal.pone.0093151. eCollection 2014. PLoS One. 2014. PMID: 24664372 Free PMC article.
-
Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date.Onco Targets Ther. 2018 Apr 12;11:2141-2147. doi: 10.2147/OTT.S147168. eCollection 2018. Onco Targets Ther. 2018. PMID: 29695920 Free PMC article. Review.
-
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. doi: 10.2174/156800909787580999. Curr Cancer Drug Targets. 2009. PMID: 19275762 Free PMC article. Review.
-
[Value of targeted therapy for prostate cancer].Urologe A. 2008 Oct;47(10):1315-9. doi: 10.1007/s00120-008-1748-8. Urologe A. 2008. PMID: 18587554 German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
